DR REDDYS LABORATORIES LTD — Capital/Financing Update 2025

Jul 25, 2025

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com

July 25, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is in furtherance to our intimation dated November 5, 2024, wherein we had informed that the Board has approved the fund infusion by way of investment in equity shares of Dr. Reddy's Laboratories LLC, Russia, a step-down wholly-owned subsidiary ("DRL Russia"), upto an amount of Rs.600 Crores.

In this connection, we further inform that the Company has made an investment of Rs. 565,40,77,993/- in DRL Russia for a total equity stake of 45.19%.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above fund infusion is given in Annexure enclosed herewith.

This is for your information and records.

Thanking you.

Yours faithfully, For Dr. Reddy's Laboratories Limited

KUMAR RANDHIR SINGH Digitally signed by KUMAR RANDHIR SINGH Date: 2025.07.25 19:17:07 +05'30'

K Randhir Singh Company Secretary, Compliance Officer and Head-CSR

Encl: as above

Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing

Obligation and Disclosure Requirements) Regulations, 2015
Sl.No	Particulars	Description
1	Name of the target entity, details in briefsuch as size, turnover etc.	Dr. Reddy's Laboratories LLC, Russia, ("DRLRussia"), a step-down wholly-owned subsidiary ofthe Company. The fund infused by the Companyinto DRL Russia will be used for working capitalrequirements. The turnover of DRL Russia forFY2025wasRs.2,347 Cr.
2	Whether the acquisition would fall withinrelated party transaction(s) and whether thepromoter/ promoter group/ group companieshaveanyinterestintheentitybeingacquired? If yes, nature of interest anddetails thereof and whether the same is doneat "arms-length"	The investment in DRL Russia is a related partytransaction, as DRL Russia is a step-down whollyowned subsidiary and accordingly a related partyto the Company. Except as stated above, thepromoter/ promoter group/ group companies haveno interest in DRL Russia.
3	Industry to which the entity being acquiredbelongs	DRLRussiaisaPharmaceuticalcompanyregisteredinRussianFederationdistributingpharmaceutical medicines in the country.
4	Objects and effects of acquisition (includingbut not limited to, disclosure of reasons foracquisition of target entity, if its business isoutside the main line of business of the listedentity)	The fund infused by the Company into DRL Russiawill be used for working capital requirements.
5	Briefdetailsofanygovernmentalorregulatoryapprovalsrequiredfortheacquisition	Not Applicable
6	Indicative time period for completion of theacquisition	The Company has acquired total equity stake of45.19% in DRL Russia on July 25, 2025.
7	Natureofconsideration-whethercashconsideration or share swap or any otherform and details of the same	Cash consideration
8	Cost of acquisition and/or the price at whichthe shares are acquired	Cash consideration of Rs. 565,40,77,993/- towardstotal equity stake of 45.19% in DRL Russia.
9	Percentageofshareholding/controlacquired and / or number of shares acquired	DRL Russia is a step- down wholly ownedsubsidiary of the Company.
10	Brief background about the entity acquiredintermsofproducts/lineofbusinessacquired, date of incorporation, history oflast 3 years turnover, country in which theacquired entity has presence and any othersignificant information (in brief)	DRLRussiaisaPharmaceuticalcompanyregisteredinRussianFederationdistributingpharmaceutical medicines in the country. Thecompany was incorporated on 5th of April 2003.The turnover of the company for the previous 3years is shown in below table:FY 2025Rs.2347 CrFY 2024Rs.2084 CrFY 2023Rs.1915 Cr